Acknowledgement
This research was supported by Changwon National University in 2021~2022.
References
- Jung CH, Son JW, Kang S, Kim WJ, Kim HS, Kim HS, et al. Diabetes fact sheets in Korea, 2020: an appraisal of current status. Diabetes Metab J 2021; 45(1): 1-10. https://doi.org/10.4093/dmj.2020.0254
- Giri B, Dey S, Das T, Sarkar M, Banerjee J, Dash SK. Chronic hyperglycemia mediated physiological alteration and metabolic distortion leads to organ dysfunction, infection, cancer progression and other pathophysiological consequences: an update on glucose toxicity. Biomed Pharmacother 2018; 107: 306-328. https://doi.org/10.1016/j.biopha.2018.07.157
- Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res 2010; 107(9): 1058-1070. https://doi.org/10.1161/CIRCRESAHA.110.223545
- Singh VP, Bali A, Singh N, Jaggi AS. Advanced glycation end products and diabetic complications. Korean J Physiol Pharmacol 2014; 18(1): 1-14. https://doi.org/10.4196/kjpp.2014.18.1.1
- Li J, Shangguan H, Chen X, Ye X, Zhong B, Chen P, et al. Advanced glycation end product levels were correlated with inflammation and carotid atherosclerosis in type 2 diabetes patients. Open Life Sci 2020; 15(1): 364-372. https://doi.org/10.1515/biol-2020-0042
- Nowotny K, Jung T, Hohn A, Weber D, Grune T. Advanced glycation end products and oxidative stress in type 2 diabetes mellitus. Biomolecules 2015; 5(1): 194-222. https://doi.org/10.3390/biom5010194
- Tobon-Velasco JC, Cuevas E, Torres-Ramos MA. Receptor for AGEs (RAGE) as mediator of NF-κB pathway activation in neuroinflammation and oxidative stress. CNS Neurol Disord Drug Targets 2014; 13(9): 1615-1626. https://doi.org/10.2174/1871527313666140806144831
- Indyk D, Bronowicka-Szydelko A, Gamian A, Kuzan A. Advanced glycation end products and their receptors in serum of patients with type 2 diabetes. Sci Rep 2021; 11(1): 13264. https://doi.org/10.1038/s41598-021-92630-0
- Xu GW, Yao QH, Weng QF, Su BL, Zhang X, Xiong JH. Study of urinary 8-hydroxydeoxyguanosine as a biomarker of oxidative DNA damage in diabetic nephropathy patients. J Pharm Biomed Anal 2004; 36(1): 101-104. https://doi.org/10.1016/j.jpba.2004.04.016
- Dong QY, Cui Y, Chen L, Song J, Sun L. Urinary 8-hydroxydeoxyguanosine levels in diabetic retinopathy patients. Eur J Ophthalmol 2008; 18(1): 94-98. https://doi.org/10.1177/112067210801800116
- Panchenko MV, Farber HW, Korn JH. Induction of heme oxygenase-1 by hypoxia and free radicals in human dermal fibroblasts. Am J Physiol Cell Physiol 2000; 278(1): C92-C101. https://doi.org/10.1152/ajpcell.2000.278.1.c92
- Bao W, Rong S, Zhang M, Yu X, Zhao Y, Xiao X, et al. Plasma heme oxygenase-1 concentration in relation to impaired glucose regulation in a non-diabetic Chinese population. PLoS One 2012; 7(3): e32223. https://doi.org/10.1371/journal.pone.0032223
- Bao W, Song F, Li X, Rong S, Yang W, Zhang M, et al. Plasma heme oxygenase-1 concentration is elevated in individuals with type 2 diabetes mellitus. PLoS One 2010; 5(8): e12371. https://doi.org/10.1371/journal.pone.0012371
- Rasool M, Malik A, Butt TT, Ashraf MAB, Rasool R, Zahid A, et al. Implications of advanced oxidation protein products (AOPPs), advanced glycation end products (AGEs) and other biomarkers in the development of cardiovascular diseases. Saudi J Biol Sci 2019; 26(2): 334-339. https://doi.org/10.1016/j.sjbs.2018.08.024
- Smit AJ, Lutgers HL. The clinical relevance of advanced glycation endproducts (AGE) and recent developments in pharmaceutics to reduce AGE accumulation. Curr Med Chem 2004; 11(20): 2767-2784. https://doi.org/10.2174/0929867043364342
- van Waateringe RP, Slagter SN, van Beek AP, van der Klauw MM, van Vliet-Ostaptchouk JV, Graaff R, et al. Skin autofluorescence, a non-invasive biomarker for advanced glycation end products, is associated with the metabolic syndrome and its individual components. Diabetol Metab Syndr 2017; 9(1): 42. https://doi.org/10.1186/s13098-017-0241-1
- Choi EY, Kwon HM, Ahn CW, Lee GT, Joung B, Hong BK, et al. Serum levels of advanced glycation end products are associated with in-stent restenosis in diabetic patients. Yonsei Med J 2005; 46(1): 78-85. https://doi.org/10.3349/ymj.2005.46.1.78
- Shin HY, Kang HT. Recent trends in the prevalence of underweight, overweight, and obesity in Korean adults: The Korean National Health and Nutrition Examination Survey from 1998 to 2014. J Epidemiol 2017; 27(9): 413-419. https://doi.org/10.1016/j.je.2016.08.014
- Smith U. Abdominal obesity: a marker of ectopic fat accumulation. J Clin Invest 2015; 125(5): 1790-1792. https://doi.org/10.1172/JCI81507
- Lim S, Meigs JB. Links between ectopic fat and vascular disease in humans. Arterioscler Thromb Vasc Biol 2014; 34(9): 1820-1826. https://doi.org/10.1161/ATVBAHA.114.303035
- Jeon J, Jung KJ, Jee SH. Waist circumference trajectories and risk of type 2 diabetes mellitus in Korean population: the Korean Genome and Epidemiology Study (KoGES). BMC Public Health 2019; 19(1): 741. https://doi.org/10.1186/s12889-019-7077-6
- Kim TJ, Kim HJ, Kim YB, Lee JY, Lee HS, Hong JH, et al. Comparison of surrogate markers as measures of uncomplicated insulin resistance in Korean adults. Korean J Fam Med 2016; 37(3): 188-196. https://doi.org/10.4082/kjfm.2016.37.3.188
- Rhee EJ, Kim HC, Kim JH, Lee EY, Kim BJ, Kim EM, et al. 2018 Guidelines for the management of dyslipidemia in Korea. Korean J Intern Med 2019; 34(5): 1171. https://doi.org/10.3904/kjim.2019.188.e1
- Hirano T. Pathophysiology of diabetic dyslipidemia. J Atheroscler Thromb 2018; 25(9): 771-782. https://doi.org/10.5551/jat.rv17023
- Jideonwo V, Hou Y, Ahn M, Surendran S, Morral N. Impact of silencing hepatic SREBP-1 on insulin signaling. PLoS One 2018; 13(5): e0196704. https://doi.org/10.1371/journal.pone.0196704
- Su W, Cao R, He YC, Guan YF, Ruan XZ. Crosstalk of hyperglycemia and dyslipidemia in diabetic kidney disease. Kidney Dis (Basel) 2017; 3(4): 171-180. https://doi.org/10.1159/000479874
- Cornier MA, Dabelea D, Hernandez TL, Lindstrom RC, Steig AJ, Stob NR, et al. The metabolic syndrome. Endocr Rev 2008; 29(7): 777-822. https://doi.org/10.1210/er.2008-0024
- Robins SJ, Lyass A, Zachariah JP, Massaro JM, Vasan RS. Insulin resistance and the relationship of a dyslipidemia to coronary heart disease: the Framingham Heart Study. Arterioscler Thromb Vasc Biol 2011; 31(5): 1208-1214. https://doi.org/10.1161/ATVBAHA.110.219055
- Vladu IM, Fortofoiu M, Clenciu D, Fortofoiu MC, Padureanu R, Radu L, et al. Insulin resistance quantified by the value of HOMA-IR and cardiovascular risk in patients with type 2 diabetes. Exp Ther Med 2022; 23(1): 73.
- Leslie RD, Cohen RM. Biologic variability in plasma glucose, hemoglobin A1c, and advanced glycation end products associated with diabetes complications. J Diabetes Sci Technol 2009; 3(4): 635-643. https://doi.org/10.1177/193229680900300403
- Kass DA, Shapiro EP, Kawaguchi M, Capriotti AR, Scuteri A, deGroof RC, et al. Improved arterial compliance by a novel advanced glycation end-product crosslink breaker. Circulation 2001; 104(13): 1464-1470. https://doi.org/10.1161/hc3801.097806
- Grindel A, Guggenberger B, Eichberger L, Poppelmeyer C, Gschaider M, Tosevska A, et al. Oxidative stress, DNA damage and DNA repair in Female patients with diabetes mellitus type 2. PLoS One 2016; 11(9): e0162082. https://doi.org/10.1371/journal.pone.0162082
- Otterbein LE, Choi AM. Heme oxygenase: colors of defense against cellular stress. Am J Physiol Lung Cell Mol Physiol 2000; 279(6): L1029-L1037. https://doi.org/10.1152/ajplung.2000.279.6.L1029
- Kirino Y, Takeno M, Iwasaki M, Ueda A, Ohno S, Shirai A, et al. Increased serum HO-1 in hemophagocytic syndrome and adult-onset Still's disease: use in the differential diagnosis of hyperferritinemia. Arthritis Res Ther 2005; 7(3): R616-R624. https://doi.org/10.1186/ar1721
- He M, Siow RC, Sugden D, Gao L, Cheng X, Mann GE. Induction of HO-1 and redox signaling in endothelial cells by advanced glycation end products: a role for Nrf2 in vascular protection in diabetes. Nutr Metab Cardiovasc Dis 2011;21(4): 277-285. https://doi.org/10.1016/j.numecd.2009.12.008